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Abstract In patients with congestive heart failure (CHF), a
high prevalence of sleep-disordered breathing has been
described. Cheyne-Stokes respiration (CSR) is present in up
to 40% of patients with CHF. During the last decade, the
medical treatment has been substantially improved. This
study was designed to analyze the prognosis of CSR in
modern-treated patients with CHF. For this purposes, in 57
patients with CHF who received modern treatment, a 5-year
follow-up after initial full night polysomnography was per-
formed. The mean follow-up period was 38 ± 18 months.
Mean age was 62 ± 13 years and the mean ejection fraction
was 25 ± 7 percent. Respiratory polygraphy revealed CSR
with a respiratory disturbance index[5 per hour of sleep in
39 of 57 patients. Twelve patients died. CSR was only
characterized by a tendency of worsening (log-rank test,
p = 0.25). However, there was a significant difference
toward positive outcome for patients who received cardiac
resynchronization therapy (log-rank test, p = 0.036). Using
Multivariate Cox’s proportional hazard regression with the
factors resynchronization and CSR, the effect of resyn-
chronization was almost significant (p = 0.08). In conclu-
sion, no significant change of Cheyne-Stokes prevalence can
be found in our small group of modern-treated patients with
CHF. Cardiac resynchronization therapy was associated
with improved patient outcome.
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Introduction
Congestive heart failure is one of the leading causes of
morbidity and mortality in developed countries. In recent
years, there has been a high prevalence of sleep-disordered
breathing in patients with congestive heart failure [1–4].
Since the description of waxing and waning breathing
pattern by Cheyne and Stokes, the occurrence of Cheyne-
Stokes respiration is well recognized in congestive heart
failure [5, 6]. Several investigators have shown an
increased mortality in congestive heart failure combined
with Cheyne-Stokes respiration [7–9]. Possibly this is
based on an increased neurohumoral stress on the heart
[10]. The treatment of patients with congestive heart failure
has changed during the last decade as new therapeutic
standards, such as beta-blockers and angiotensin-convert-
ing-enzyme inhibitors, have been established [11, 12]. The
prognosis for patients with congestive heart failure could
be substantially improved by these.
Recent investigations have focused on changes in prev-
alence of sleep-breathing disorders. In 203 German patients
with congestive heart failure and left ventricular ejection
fraction \40%, an apnea-hypopnea index cutoff of
approximately 10 per hour were seen by polygraphy in 71%
with a majority in obstructive sleep apnea probably due to
higher body mass index [13]. In a retrospective analysis in
450 consecutive patients with congestive heart failure with
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an apnea-hypopnea index cutoff of approximately 10 per
hour, Sin et al. found a prevalence of sleep-disordered
breathing of 72% [14]. In this retrospective analysis, the
prevalence of Cheyne-Stokes respiration with 33% was
comparable to the German patients with 28% [13]. In con-
trast, the prevalence of sleep-disordered breathing according
to common study criteria with an apnea-hypopnea index
cutoff of approximately 10 per hour in 81 patients with
congestive heart failure has been approximately 50% [1].
The differences compared to the findings of Javaheri et al.
are possibly the result of a higher body mass index, leading
to an increased prevalence of obstructive sleep apneas.
Furthermore, there was no predefined inclusion ejection
fraction in Sins’ patient collective.
However, if there is a reduction of CSR and an impact of
CSR on prognosis, we would expect a reduction of mor-
tality in modern-treated congestive heart failure. This could
even be forced by a new treatment option, such as cardiac
resynchronization therapy, with proven influence on prev-
alence of CSR [15].
This study was designed to analyze the prognosis of
sleep-disordered breathing, such as Cheyne-Stokes respi-
ration, in patients suffering from modern-treated conges-
tive heart failure.
Methods
All patients admitted to the internal medicine department
at our University Hospital with heart failure were eligible
if they met the following criteria: left ventricular ejec-
tion fraction B35%, and at least one episode of cardiac
decompensation in the patient’s history. They all had to be
in stable cardiac conditions at NYHA-classification class
2–3 with no episode of decompensation at least during the
last 6 weeks. Most patients were outpatients, but also
inpatients with stable cardiac conditions were eligible. All
of them had to have a beta-blocker and an angiotensin-
converting-enzyme inhibitor or an angiotensin-II-antago-
nist as standard medication. No primary lung dysfunction
with a forced expiratory volume in 1 second \65% was
accepted for participants, and no myocardial infarction
should have been occurred during the last 6 months. The
minimum age for patients was 18 years.
All patients provided informed consent to participate in
the study, which was performed in accordance with the
principles of the Declaration of Helsinki and approved by
the ethics committee at the University of Goettingen.
Polysomnography was performed in one night at the sleep
laboratory of the cardiology and pneumology department
during 2003–2004. No patient had a known history of
sleep-disordered breathing before our investigations. To
determine the stages of sleep, an electroencephalogram, a
chin electromyogram, and an electrooculogram were
obtained. Thoracoabdominal excursions were measured
with electrodes placed on the rib cage and abdomen. Airflow
was monitored with thermocouples. All polysomnographic
data were collected by computer system (Alice 4, Heinen &
Lo¨wenstein, Germany). According to the criteria of the
American Academy of Sleep Medicine, there had to be at
least three cycles of crescendo and decrescendo change in
breathing amplitude and five or more central sleep apneas or
hypopneas per hour of sleep to be scored as Cheyne-Stokes
respiration [16]. Furthermore, according to common study
criteria, the apnea-hypopnea index (AHI) of [10 per hour
was defined as relevant.
Statistical analysis was performed with Statistica (GmbH
Software, Germany). The Mann–Whitney test was used to
assess differences between patients with and those without
sleep-disordered breathing, and chi-square analysis was used
to analyze proportions. Kaplan–Meier plots and log-rank test
were performed for mortality with censored patients due to
transplantation or end of follow-up time. Finally, multivar-
iate Cox’s Proportional Hazard Regression was used to asses
the effect of CSR and biventricular pacing on survival status
including age, gender, and cardiac cachexia. P \ 0.05 was
considered to indicate statistical significance. Values are
reported as mean ± standard deviation.
Results
Fifty-seven patients were included in the study (Table 1);
24 patients had a dilated and 4 had a hypertrophic nonob-
structive, whereas 29 had an ischemic cardiomyopathy.
During follow-up, 12 patients died and 4 received cardiac
transplantation. No patient was lost to follow-up. Five of the
9 women and 34 of the 48 men had CSR. Only three men
had predominant obstructive sleep-breathing disorders.
Beta-blocker-medication was given to all 57 patients, and
48 were treated with angiotensin-converting-enzyme inhib-
itor, whereas 9 had angiotensin-II-antagonists. All patients
had diuretic medications, and 17 were treated with digitalis.
Twenty patients received an aldosterone antagonist. Ongo-
ing amiodarone treatment could be evaluated in 14 patients.
According to the mentioned AASM criteria, eight
patients had an AHI of \5 per hour. If common criteria
from sleep investigations were used, there would have been
22 patients (44%) with an AHI of \10 per hour. Sleep-
breathing disorders defined by a respiratory disturbance
index (RDI) of [5 hour were seen in 74% of our patient
group; 68% of all study patients had Cheyne-Stokes
breathing patterns (Table 2).
Follow-up lasted for 38 ± 18 months, and no patient
was lost to follow-up. For all patients included in our
analysis, the mortality tended to be lower in CSR patients
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than in non-CSR patients without statistical significance
(log-rank test, p = 0.25; Fig. 1). Neither age nor sex
showed a significant difference in both groups.
In a smaller group of 35 patients without biventricular
pacing, the mortality was 6 of 15 (40%) in non-CSR and 7 of
20 (35%) in CSR patients group. Figure 2 shows the cumu-
lative proportion that survived (log-rank test, p = 0.42).
Comparison of patients with versus without cardiac
resynchronization therapy revealed a significant difference
in mortality (log-rank test, p = 0.036; Fig. 3). In the
multivariate Cox’s proportional hazard regression, the
combination of CSR and cardiac resynchronization therapy
could only show a tendency for positive influence of
resynchronization (hazard ratio, 0.32; 95% confidence
interval, 0.09–1.16; p = 0.08).
Discussion
Cheyne-Stokes respiration is a common sleep-breathing
disorder in patients with congestive heart failure [1–4].
Previous studies also have documented poorer prognosis
Table 1 Clinical data of the patients
Variable Patients (n = 57) CSR (n = 39) NCSR (n = 18) P value
Age (yr) 62.4 ± 12.8 61.9 ± 13.7 63.3 ± 10.9 NS
Height (cm) 174.8 ± 9.5 176.7 ± 9.5 170.8 ± 8.4 \0.05
Body mass index (kg/ m2) 26.4 ± 4.2 25.9 ± 3.7 27.3 ± 5.1 NS
Ejection fraction (%) 25.3 ± 6.5 25 ± 6 26 ± 7 NS
LVED (mm) 64.4 ± 8.3 66 ± 7 61 ± 10 \0.05
VO2max (ml/min/kg) 12.4 ± 4.1 (n = 30) 13.3 ± 4.3 (n = 20) 10.5 ± 3.1 (n = 10) 0.1
CSR patients with Cheyne-Stokes respiration according to AASM-criteria, NCSR non-Cheyne-Stokes Respiration patients; NS not significant,
LVED left ventricular end-diastolic diameter; VO2max = peak oxygen consumption
Table 2 Characteristics of the
patients during sleep
CSR patients with Cheyne-
Stokes respiration according to
AASM criteria, NCSR non-
Cheyne-Stokes respiration
patients, TST total sleep time,
REM rapid eye movement
sleep, RDI respiratory
disturbance index, AHI apnea-
hypopnea index, NS not
significant
Variable CSR (n = 39) NCSR (n = 18) P value
Total sleep time (min) 315 ± 64 288 ± 100 NS
Non-REM (min) 278 ± 56 256 ± 79 NS
REM (min) 53 ± 26 46 ± 32 NS
RDI (/h TST) 26 ± 15 12 ± 20 \0.00005
AHI (/h) 22 ± 13 10 ± 19 \0.00005
Apnea index (/h sleep) 12 ± 13 7 ± 18 \0.0005
Arousal index (/h sleep) 25 ± 13 31 ± 19 NS
Mean oxygen saturation (%) 90 ± 4 90 ± 3 NS
Minimum oxygen saturation (%) 81 ± 7 84 ± 8 NS
Fig. 1 Cumulative proportion surviving for all patients.
CSA = Cheyne-Stokes respiration; time = months; log-rank test,
p = 0.25
Fig. 2 Mortality in 35 patients without biventricular pacing.
CSA = Cheyne-Stokes respiration; time = months; log-rank test,
p = 0.42
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for this study population [7–9]. Modern medical treatment
has a prognostic impact for patients with congestive heart
failure [11, 12, 17, 18].
In a small study population of eight patients, Walsh and
colleagues showed a reduction of apneic episodes as well
as arousals and an increase of slow wave and REM sleep
by treatment with captopril [19]. The prevalence of sleep-
disordered breathing according to common study criteria
with an apnea-hypopnea index cutoff of approximately 10
per hour in a historic collective of Javaheri et al. has been
approximately 50% [1]. Still in that earlier investigation,
no standard medical treatment was given as recommended
by modern heart failure treatment guidelines [17]. As
reported at the beginning, other investigators found a
decline in prevalence by polygraphic investigation [13].
The strongest effect of modern treatment of congestive
heart failure and prevalence of CSR was seen in cardiac
resynchronization therapy [15]. Treatment reduction of CSR
as well as an association of CSR reduction with improved
sleep quality and quality of life was evident in 42 patients
with heart failure by Skobel et al. [20]. A reduction in
mortality for patients with congestive heart failure was
described in the meta-analyses by Rivero-Ayerza et al. [21].
In our study population, this reduction in mortality during a
5-year follow-up also was shown (p \ 0.04). However, no
clear evidence for an association with CSR could be estab-
lished from our data. Probably due to small sample size, the
benefit of cardiac resynchronization showed only a tendency
(p = 0.08). Furthermore, sleep investigations during fol-
low-up for analysis of CSR reduction due to implantation of
resynchronization aggregates were not obtained.
Conclusions
There appears to be no prognostic benefit for the modern
medical treatment in association with CSR, although
improved prognostic outcome in congestive heart failure is
known. For nonpharmacologic treatments, such as cardiac
resynchronization therapy, a tendency toward a beneficial
influence in CSR and a significant benefit for all patients
with congestive heart failure receiving resynchronization is
shown. Further clinical studies have to prove this hypoth-
esis of a significant correlation between CSR reduction and
outcome in patients with congestive heart failure.
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